Predictive Oncology (POAI) announced that positive results from an ongoing study in collaboration with Switzerland-based Tecan, Ltd. were recently presented at the 2025 Society for Laboratory Automation and Screening International Conference & Exhibition, which was held January 25-29, 2025, in San Diego, CA. Optimized growth conditions and drug treatment protocols were established for tumor models derived from cryopreserved DTCs of different cancer types. 3D models are closer to in vivo physiological conditions than 2D models, and as expected, differences in response to drug dosing are observed.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on POAI:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue